CURE’s breast cancer page is an extensive resource of cancer information featuring the latest breast cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on breast cancer.
November 21st 2024
Aerobic exercise improved self-reported cognitive function in women undergoing chemotherapy for breast cancer but had no effect on objective cognitive function.
FDA Grants Accelerated Approval to Keytruda-Chemotherapy Combination for TNBC
November 13th 2020The Food and Drug Administration has approved the combination of Keytruda (pembrolizumab) with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer who have a PD-L1 expression.
Love and Marriage: Tackling Two Bouts of Cancer Together
November 12th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with a couple that has been married for 41 years about their journey as patient and caregiver during two bouts of triple-negative breast cancer. The couple, Janice and Rex Cowden, also give others facing similar situations advice on how to persevere together.
Katie Couric and Paula Schneider: Sharing Cancer Journeys One Letter At a Time
October 29th 2020In this episode of the “CURE Talks Cancer” podcast, we spoke with television journalist Katie Couric and Susan G. Komen CEO Paula Schneider about their experiences with cancer, and the advice they offered their pre-cancer selves.
Dose-Dense Chemotherapy Improves Disease-Free Survival in HR+/HER2- Breast Cancer
October 13th 2020Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.
Tecentriq Combo Improves Response Rates in Early TNBC, Regardless of PD-L1 Status
September 22nd 2020Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.